Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05923866 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
A Phase 2 study of Multiple System Atrophy (MSA), sponsored by Ono Pharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT05923866: Active Phase 2 study of Multiple System Atrophy (MSA), sponsored by Ono Pharmaceutical Co..
NCT05923866 is a Phase 2 study of Multiple System Atrophy (MSA) that is active but no longer recruiting, run by Ono Pharmaceutical Co.. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05923866, a Phase 2 study of Multiple System Atrophy (MSA), is active but no longer recruiting, sponsored by Ono Pharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Primary Outcome
Incidence of TEAEs, drug-related TEAEs, TEAEs resulting in study treatment discontinuation, TESAEs, and drug-related TESAEs will be tabulated by system organ class (SOC), preferred term (PT), and severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ONO-2808
Study Locations (20)
California
- The Parkinson's Movement and Disorder Institute - Fountain Valley
- University of Southern California - Los Angeles
- David Geffen School of Medicine at UCLA - Los Angeles
- Stanford University School of Medicine - Palo Alto
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Norman Fixel Institute for Neurological Diseases - University of Florida - Gainesville
- Mayo Clinic in Florida - Jacksonville
- University of Miami Miller School of Medicine - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan School of Medicine - Ann Arbor
- Quest Research Institute - Farmington Hills
New York
- NYU Langone Health - NYU Dysautonomia Center - New York
- Icahn School of Medicine at Mount Sinai - New York
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Connecticut
- Yale School of Medicine - Yale Church Street Research Unit (CRSU) - New Haven
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 2 |
What the registry record for NCT05923866 still lists
NCT05923866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Multiple System Atrophy (MSA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05923866 names 20 study sites across 11 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05923866 about?
NCT05923866 is a clinical study titled "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy". This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
What is the current status of trial NCT05923866?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2023-09-22. Estimated completion is 2025-08-31.
What conditions does trial NCT05923866 study?
This clinical trial studies the following conditions: Multiple System Atrophy (MSA).
What interventions are being tested in trial NCT05923866?
The interventions under investigation include: Placebo (DRUG), ONO-2808 (DRUG).
Who is sponsoring clinical trial NCT05923866?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05923866 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy (MSA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05923866's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI